Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) saw an uptick in trading volume on Monday . 1,416,248 shares traded hands during trading, an increase of 127% from the previous session’s volume of 624,918 shares.The stock last traded at $0.43 and had previously closed at $0.38.

Separately, S&P Equity Research dropped their target price on Repros Therapeutics from $0.49 to $0.39 in a report on Monday.

Repros Therapeutics (NASDAQ:RPRX) last released its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.24. The firm had revenue of $0.30 million for the quarter. Repros Therapeutics had a negative net margin of 4,242.73% and a negative return on equity of 894.22%.

An institutional investor recently raised its position in Repros Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 1.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 727,113 shares of the biotechnology company’s stock after purchasing an additional 10,700 shares during the period. Renaissance Technologies LLC owned 2.73% of Repros Therapeutics worth $873,000 as of its most recent SEC filing. 13.13% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.